BTBegoña Tortajada-Goitia

Begoña Tortajada-Goitia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Begoña Tortajada-Goitia has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Análisis de la concordancia entre la estratificación teórica y real en pacientes que viven con la infección por VIH atendidos en un hospital de tercer nivel

    by Rocío Asensi-Diez, Ángel Ballesteros-Fernández, Manuel Rouco, Begoña Tortajada-Goitia, Aránzazu Linares-Alarcón

    Introducción: Analizar la concordancia entre la estratificación teórica y la real de las personas que viven con la infección por VIH atendidas en una consulta de atención farmacéutica de pacientes externos de un hospital regional de tercer nivel. Material y métodos: Estudio observacional, retrospectivo, analítico, de corte transversal y unicéntrico en las personas que viven con la infección VIH. Periodo de estudio: abril de 2024. Criterios de inclusión: pacientes con infección por VIH mayores de 18 años que hubieran recibido tratamiento antirretroviral (TAR) activo durante al menos dos años antes de su inclusión. Se utilizó el modelo de estratificación de atención farmacéutica para personas con la infección por VIH, versión año 2022. Se evaluó la fiabilidad desde una perspectiva cualitativa mediante el coeficiente Kappa de Cohen. Resultados: De los 199 pacientes atendidos en el periodo de estudio, se seleccionaron correlativamente 100 pacientes, de los cuales finalmente se estratificaron 93. El 77,41% eran hombres, con una media de edad de 47,81 ± 12,53 años. Los porcentajes de estratificación obtenidos fueron: Prioridad 1: 7,52%; Prioridad 2: 26,88%; Prioridad 3: 65,59%. El análisis cuantitativo de la concordancia entre los modelos mostró un coeficiente Kappa de Cohen de K=0,866. Conclusiones: Existe una buena concordancia entre los porcentajes de distribución de la estratificación teórica y la real obtenida.


  • Open Access

    Outpatients’ Opinion And Experience Regarding Telepharmacy During The COVID-19 Pandemic: The Enopex Project

    by Luis Margusino-Framiñán, Cecilia M Fernández-Llamazares, Eva Negro-Vega, Begoña Begoña Tortajada-Goitia, Garbiñe Lizeaga, Gabriel Mercadal-Orfila, Carmen Almeida-González, Ramón Morillo-Verdugo

    Background: Telepharmacy, as a remote pharmaceutical care procedure, is being used worldwide during the COVID-19 pandemic, with the aim of preserving the health of patients and professionals. Its future development should incorporate the assessment of patient perception, but no research study has investigated it. Objective: The objective was to poll the opinions and experiences of outpatients with telepharmacy through a purpose-developed questionnaire and to assess it’s quality through an internal validity and reliability analysis. Methods: Cross-sectional observational study of adult patients who used telepharmacy services during the COVID-19 lockdown period in Spain. The subjects answered a 24-item questionnaire, after giving their informed consent. Place of delivery, informed pharmacotherapeutic follow-up, opinion about telepharmacy, future development, ethics/satisfaction, and coordination constituted the six questionnaire categories. After assessing the adequate sample size with the Kaiser–Meyer–Olkin test, the Bartlett sphericity test analyzed the validity of the questionnaire. The intraclass correlation coefficient and Cronbach’s α coefficient calculations verified the reliability and internal consistency. Results: A total of 9442 interviews were administered to patients from 81 hospitals, of which 8079 were valid (52.8% female). A 54.1% were aged between 41– 65 years; 42.7% had been in treatment for more than 5 years; 42.8% lived between 6– 31 miles from the hospital. As many as 96.7% of patients were “satisfied” or “very satisfied” with telepharmacy, 97.5% considering it complementary to their usual follow-up; 55.9% expressed a preference for being followed up face to face when visiting the hospital. 75.6% said they had rather receive their medication at home. The sample size obtained was deemed appropriate [the Kaiser–Meyer–Olkin test (0.789) and Bartlett’s sphericity test (p< 0.005)]. The reliability analysis resulted in a Cronbach α = 0.7. Conclusion: Patients have shown high satisfaction with telepharmacy and the ENOPEX questionnaire is a tool with sufficient validity and reliability to be used in the evaluation of the care that patients receive through telepharmacy.


  • Desarrollo de la norma Q-PEX de certificación de calidad de la atención farmacéutica a pacientes externos de los servicios de Farmacia

    by R. Morillo Verdugo, M. Calvin Lamas, A.T.J. Delgado Latorre, R. Ferrando Piqueres, C.M. Fernández-Llamazares, E. Negro Vega, B. Tortajada Goitia


  • Survey on the situation of telepharmacy as applied to the outpatient care in hospital pharmacy departments in Spain during the COVID-19 pandemic

    by Begona Tortajada-Goitia, Ramon Morillo-Verdugo, Luis Margusino-Framinan, Jose Antonio Marcos, Cecilia M. Fernandez-Llamazares

    Objective: To analyze the status of the implementation and development of telepharmacy as applied to the pharmaceutical care of outpatients treated at hospital pharmacy services in Spain during the COVID-19 pandemic. Method: Six weeks after the beginning of the confinement period, an online 10-question survey was sent to all members of the Spanish Society of Hospital Pharmacists. A single response per hospital was requested. The survey included questions on the provision of remote pharmaceutical care prior to the onset of the health crisis, patient selection criteria, procedures for home delivery of medications and the means used to deliver them, the number of patients who benefited from telepharmacy, and the number of referrals made. Finally, respondents were asked whether a tele-consultation was carried out before sending patients their medication and whether these deliveries were recorded. Results: A total of 39.3% (n = 185) of all the hospitals in the National Health System (covering all of Spain's autonomous regions) responded to the survey. Before the beginning of the crisis, 83.2% (n = 154) of hospital pharmacy services did not carry out remote pharmaceutical care activities that included telepharmacy with remote delivery of medication. During the study period, 119,972 patients were treated, with 134,142 deliveries of medication being completed. Most hospitals did not use patient selection criteria. A total of 30.2% of hospitals selected patients based on their personal circumstances. Home delivery and informed delivery (87%; 116,129 deliveries) was the option used in most cases. The means used to deliver the medication mainly included the use of external courier services (47.0%; 87 hospitals) or the hospital's own transport services (38.4%; 71 hospitals). As many as 87.6% of hospitals carried out teleconsultations prior to sending out medications and 59.6% recorded their telepharmacy activities in the hospital pharmacy appointments record. Conclusions: The rate of implementation of telepharmacy in outpatient care in Spain during the study period in the pandemic was high. This made it possible to guarantee the continuity of care for a large number of patients.


  • Open Access

    Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks

    by Julián Olalla, Javier Pérez-Stachowski, Begoña Tortajada, Alfonso Del Arco, Efrén Márquez, Javier De la Torre, Miriam Nieto, José María García de Lomas, José Luis Prada, Javier García-Alegría

    Background: Generic drugs may help to support antiretroviral treatment. We want to assess the efficacy and safety at 24 weeks of the change of coformulated (abacavir + lamivudine + dolutegravir) to (abacavir + lamivudine) coformulated as a generic pharmaceutical specialty + dolutegravir. Methods: Between February and June 2017, switch from Triumeq® to a generic pharmaceutical specialty co-formulated tablet (abacavir + lamivudine) plus Tivicay® was made. Demographic, viroimmunological characteristics and the Charlson index were collected. Six months after switching, efficacy and safety were evaluated. Results: Switch was made in 93 patients, with a mean age of 47 years, after six months there were five patients (5.4%) with viral loads between 50 and 400 copies, no patient had viral loads of greater amount. There were 2 interruptions due to toxicity (2.15%), in relation to symptoms of the central nervous system. There were no differences in the amount of years with HAART, nor in the previous months with the STR regimen based on abacavir + lamivudine + dolutegravir, nor in the Charlson index. The effective saving in 2017 derived from the change in these 93 patients was € 125.512. Conclusions: The change from a regimen of abacavir + lamivudine + dolutegravir seems to be safe and effective at 24 weeks.


  • Effect of a Structured Pharmaceutical Care Intervention Versus Usual Care on Cardiovascular Risk in HIV Patients on Antiretroviral Therapy: INFAMERICA Study

    by Ramón Morillo-Verdugo, María de Las Aguas Robustillo-Cortés, María Teresa Martín-Conde, Gador Callejón-Callejón, Purificación Cid-Silva, Carmen Moriel-Sánchez, Begoña Tortajada-Goitia, Carmen Victoria Almeida-González

    Background: HIV+ patients have increased their life expectancy with a parallel increase in age-associated comorbidities. Objective: To determine the effectiveness of an intensive pharmaceutical care follow-up program in comparison to a traditional model among HIV-infected patients with moderate/high cardiovascular risk. Method: This was a multicenter, prospective, randomized study of a structured health intervention conducted between January-2014 and June-2015 with 12 months of follow-up at outpatient pharmacy services. The selected patients were randomized to a control group (usual care) or intervention group (intensive pharmaceutical care). The interventional program included follow-up of all medication taken by the patient to detect and work toward the achievement of pharmacotherapeutic objectives related to cardiovascular risk and making recommendations for improving diet, exercising, and smoking cessation. Individual motivational interview and periodic contact by text messages about health promotion were used. The primary end point was the percentage of patients who had reduced the cardiovascular risk index, according to the Framingham-score. Results: A total of 53 patients were included. As regards the main variable, 20.7% of patients reduced their Framingham-score from high/very high to moderate/low cardiovascular risk versus 12.5% in the control group (P=0.016). In the intervention group, the number of patients with controlled blood pressure increased by 32.1% (P=0.012); 37.9% of patients overall stopped smoking (P=0.001), and concomitant medication adherence increased by 39.4% at the 48-week follow-up (P=0.002). Conclusion and Relevance: Tailored pharmaceutical care based on risk stratification, motivational interviewing, and new technologies might lead to improved health outcomes in HIV+ patients at greater cardiovascular risk.


  • An admission medication reconciliation programme carried out by pharmacists: impact on surgeons' prescriptions

    by José Javier Arenas-Villafranca, Manuela Moreno-Santamaría, Carmen López Gómez, Isabel Muñoz Gómez-Millán, Elena Álvaro Sanz, Begoña Tortajada-Goitia

    Objectives To describe a medication reconciliation (MR) procedure prepared by the pharmacist for patients admitted for elective surgery and to assess the surgeon’s degree of acceptance. Methods A 1-year retrospective observational study was conducted. The patient population consisted of patients aged ≥18 years admitted during 2016 for elective surgery and whose planned length of hospital stay was >24 hours. A pharmacist performed MR following a specific protocol. A review of the reconciliations prescribed later by the surgeons was conducted. Statistical analyses were performed for qualitative and quantitative variables. Results The pharmacist prepared a total of 1986 reconciliation reports. The 179 patients reviewed in this study had a mean age of 65.7±11.8 years, 49.2% were women and 98.9% of patients were reconciled by the surgeon in the operating theatre using an electronic prescribing system (85.5% were fully reconciled). Conclusion The hospital’s MR protocol resulted in almost 100% of patients being reconciled within the subgroup of elective surgery patients by the prescribing surgeons.

  • The role of clinical pharmacists in the optimisation of medication prescription and reconciliation on admission in an emergency department

    by José Javier Arenas-Villafranca, Juan Manuel Rodríguez-Camacho, María Antonia Pérez-Moreno, Manuela Moreno-Santamaría, Francisco de Asís Martos-Pérez, Begoña Tortajada-Goitia

    Objectives To describe a clinical pharmacist’s (CP) activity in an emergency department (ED) regarding medication reconciliation and optimisation of pharmacotherapy of patients at hospital admission. Methods A 1-year prospective observational study was conducted to analyse the activity of a CP in the ED of a 350-bed hospital in Spain. The CP reviewed home medications and medical prescriptions of patients to perform medication reconciliation if required and intervene if medication errors were detected. Results The CP reviewed medications and medical orders of 1048 patients. 816 patients had home medication: 440 patients (53.9%) were correctly reconciled by the physician; 136 (16.7%) were reconciled by the physician with unintentional discrepancies; and 240 (29.4%) by the CP, with a higher percentage in patients admitted to surgical departments (χ2:38.698; P<0.001). Following pharmaceutical validation, 434 pharmaceutical interventions were performed. Conclusions The presence of a CP in an ED could increase the detection of reconciliation errors and help resolve medication errors.


  • Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection

    by Juan Manuel Lebron Ramos, Luis Fernandez de Rota Garcia, Alicia Padilla Galo, Begoña Tortajada Goitia, Jose Joaquin Cebrian Gallardo, Francisco Rivas Ruiz

    Introduction: Chronic bronchial Pseudomonas (PA) infection is associated with increased exacerbations and hospitalizations in patients with non-CF bronchiectasis (NCFBC). Aims: To demonstrate that treatment with Colistin by I-neb® reduces exacerbations and hospitalizations, and that this is related with adherence to treatment and ability to use the device. Methods: Observational study comparing exacerbations and hospitalizations in the pre- and post-initiation of treatment with Colistin year, analyzing whether adherence and ability to use the I-neb® influence the results. Results: 19 patients (68.4% male) were collected with a median age of 70(21). 100% of patients had exacerbations in the previous year, median 5(6); compared with 73.7% in the following year, median 1(3), pConclusions: Treatment with Colistin by I-neb® device reduces exacerbations and hospitalizations in patients with NCFBC and chronic PA infection. This effect on exacerbations is clearly related to adherence. The use of I-neb® is simple and helps proper drug administration in most patients.